Ironwood Pharmaceuticals Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +85.6% | +14.6% | -14.7% | -45.2% | +21.3% | +38.9% | +101.5% | -2.3% | -57.2% | -25.5% | +13.1% | |
| – | +72.6% | -24.0% | -18.0% | -14.5% | +15.2% | +61.6% | +50.3% | +4.8% | -70.1% | -21.8% | +50.3% | |
| – | +251.7% | -79.3% | +132.8% | +37.7% | +2.2% | +105.8% | +70.2% | +5.8% | -86.0% | -3.9% | +143.3% | |
| – | +76.9% | -30.5% | -27.5% | -21.8% | +2.2% | +105.8% | +70.2% | +5.8% | -86.0% | -3.9% | +143.3% | |
| – | +111.0% | +19.0% | +26.7% | -1.5% | +44.8% | +4.4% | -6.8% | +1.2% | +11.8% | -36.6% | -42.9% | |
| – | -100.0% | – | -32.0% | -100.0% | – | -100.0% | +124,999,900.0% | +0.0% | -100.0% | – | – | |
| – | -29.3% | -2.7% | -15.8% | 0.0% | -28.0% | -28.2% | +156.7% | -72.6% | – | – | – | |
| – | – | – | +0.0% | +0.0% | +0.0% | +0.0% | – | – | – | – | – | |
| – | – | – | -3.7% | – | – | – | – | – | – | -22.3% | -28.7% | |
| – | +113.9% | +22.7% | -7.4% | -11.3% | -6.1% | +0.1% | +4.9% | -14.0% | +82.4% | -20.2% | +1.0% | |
| – | +26.3% | +19.2% | -27.5% | +81.0% | -65.8% | -21.4% | +402.6% | -84.2% | +981.7% | -85.9% | +523.5% | |
| – | +122.9% | -79.4% | -34.5% | +1,068.2% | -97.6% | +172.9% | +3,735.8% | -97.4% | +6,512.9% | -98.4% | +6,263.5% | |
| – | -12.0% | +106.1% | -9.9% | -6.7% | -63.2% | -88.0% | +41.5% | -48.3% | +1,521.1% | -72.8% | +36.2% | |
| – | +117.8% | +3.7% | +8.1% | -7.6% | +11.4% | +5.5% | -21.6% | +17.5% | +25.8% | +17.2% | -34.1% | |
| – | +7.4% | -29.9% | -85.2% | -2,094.0% | – | – | +867.3% | +7.7% | -153.1% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3.9% | +2.6% | +2.1% | +2.4% | +2.2% | +3.0% | +2.3% | +13.3% | -16.6% | +3.0% | +11.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.